<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; CEPH</title>
	<atom:link href="http://www.stockbloghub.com/tag/ceph/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(SHLD) COOPER TIRE &#8211; Profit Tracks</title>
		<link>http://www.stockbloghub.com/2011/10/26/shld-cooper-tire-profit-tracks-2/85744</link>
		<comments>http://www.stockbloghub.com/2011/10/26/shld-cooper-tire-profit-tracks-2/85744#comments</comments>
		<pubDate>Wed, 26 Oct 2011 13:47:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Department Stores]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Cooper Tire & Rubber Company]]></category>
		<category><![CDATA[CTB]]></category>
		<category><![CDATA[Sears Holdings Corporation]]></category>
		<category><![CDATA[SHLD]]></category>
		<category><![CDATA[SMG]]></category>
		<category><![CDATA[The Scotts Miracle-Gro Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=85744</guid>
		<description><![CDATA[Since inception in 1988, the S&#38;P 500 has outperformed the Zacks #5 Rank List &#8211; Stocks to Sell Now by 80% annually (+2% versus +10%). While the rest of Wall Street continued to tout stocks during the market declines of the last few years, Zacks told investors which stocks to sell or avoid. Here is a synopsis of why SHLD and CTB have a Zacks Rank of #5 (Strong Sell) and should most likely be sold or avoided for the next one to three months. Note that a #5 Strong Sell rating is applied to 5% of all the stocks in the Zacks Rank universe: Sears Holdings Corporation (SHLD)announced second-quarter profit of 38 cents per share on August 18 that missed analysts? expectations by 5%. The Zacks Consensus Estimate for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/26/shld-cooper-tire-profit-tracks-2/85744/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Pharmaceuticals Stock Outlook &#8211; September 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930</link>
		<comments>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930#comments</comments>
		<pubDate>Fri, 23 Sep 2011 18:59:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ICAgen Inc]]></category>
		<category><![CDATA[ICGN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83930</guid>
		<description><![CDATA[The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance between new product launches and patent expirations. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Major revenue generating drugs like Lipitor, Plavix, Lexapro and Zyprexa are expected to confront generic competition over the next five years. In fact, revenues in excess of $30 billion are expected to be lost in 2011 itself due to key drugs like Lipitor and Zyprexa going off-patent. The impact of the genericization of these drugs will be felt significantly in 2012, which will be a challenging year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan and Endo Pharmaceuticals in Legal Tussle</title>
		<link>http://www.stockbloghub.com/2011/08/18/myl-mylan-and-endo-pharmaceuticals-in-legal-tussle/81630</link>
		<comments>http://www.stockbloghub.com/2011/08/18/myl-mylan-and-endo-pharmaceuticals-in-legal-tussle/81630#comments</comments>
		<pubDate>Thu, 18 Aug 2011 22:40:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81630</guid>
		<description><![CDATA[Mylan Inc. (MYL) recently announced that Endo Pharmaceuticals (ENDP) filed a patent infringement lawsuit in connection with an abbreviated new drug application (ANDA) filed by Mylan with the US Food and Drug Administration (FDA) for the generic version of Endo’s acute migraine drug Frova. Mylan believes it is the first company to file an ANDA for generic Frova and is expecting to be granted 180 days of marketing exclusivity once approved. Frova generated revenues of approximately $68.2 million in the trailing twelve months ending on June 30, 2011. This month, Mylan launched the generic version of Uroxatral tablets. Some important products launched by Mylan in the recent past include generic versions of AstraZeneca&#8216;s (AZN) Entocort, Novartis&#8216; (NVS) Femara and Cephalon&#8216;s (CEPH) Amrix. Mylan has a robust generic pipeline. As of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/18/myl-mylan-and-endo-pharmaceuticals-in-legal-tussle/81630/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRX) Valeant Pharmaceuticals International Beats Expectations &#8211; Ups View</title>
		<link>http://www.stockbloghub.com/2011/08/08/vrx-valeant-pharmaceuticals-international-beats-expectations-ups-view/80862</link>
		<comments>http://www.stockbloghub.com/2011/08/08/vrx-valeant-pharmaceuticals-international-beats-expectations-ups-view/80862#comments</comments>
		<pubDate>Mon, 08 Aug 2011 17:31:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Cogdell Spencer Inc.]]></category>
		<category><![CDATA[CSA]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80862</guid>
		<description><![CDATA[Valeant Pharmaceuticals International’s (VRX) second quarter 2011 earnings of 68 cents per share (excluding special items but including stock based compensation expense) beat the Zacks Consensus Estimate by 3 cents and the year-ago earnings by 8 cents per share. Bottom-line growth was driven by improved revenues. Adjusted diluted earnings, however, included an extraordinary gain of 6 cents from the sale of investment in Cephalon Inc. (CEPH). Revenues for the quarter were $609.4 million, marginally above the Zacks Consensus Estimate of $609 million and way ahead of the prior-year figure of $238.8 million. However, revenue included a one-time milestone payment of $40 million received from GlaxoSmithkline (GSK) related to the European launch of Trobalt (known as Potiga in the US). The improvement in revenues was primarily due to the September 2010 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/08/vrx-valeant-pharmaceuticals-international-beats-expectations-ups-view/80862/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Beats Second Quarter Earnings on All Fronts</title>
		<link>http://www.stockbloghub.com/2011/07/27/myl-mylan-beats-second-quarter-earnings-on-all-fronts/80033</link>
		<comments>http://www.stockbloghub.com/2011/07/27/myl-mylan-beats-second-quarter-earnings-on-all-fronts/80033#comments</comments>
		<pubDate>Thu, 28 Jul 2011 04:22:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80033</guid>
		<description><![CDATA[Mylan Inc.’s (MYL) second quarter 2011 earnings (excluding special items) of 52 cents per share were above the Zacks Consensus Estimate of 45 cents as well as the year-ago earnings of 37 cents per share. Earnings growth was driven by increase in generics revenue and improved gross margins. Quarter in Details Total revenues at Mylan climbed 15% over the prior year to $1.57 billion driven by increased sales of generic drugs and the positive impact of foreign exchange (Fx). Revenues were also ahead of the Zacks Consensus Estimate of $1.50 billion. Total revenues comprise both net revenues and other revenues from third parties. Mylan reports revenues through two segments: Generics and Specialty. Generic third party net sales, derived from sales in North America, Europe, Middle East &#38; Africa (EMEA), and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/27/myl-mylan-beats-second-quarter-earnings-on-all-fronts/80033/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENDP) Endo Pharmaceuticals&#8217; Back Pain Drug Disappoints</title>
		<link>http://www.stockbloghub.com/2011/07/05/endp-endo-pharmaceuticals-back-pain-drug-disappoints/78262</link>
		<comments>http://www.stockbloghub.com/2011/07/05/endp-endo-pharmaceuticals-back-pain-drug-disappoints/78262#comments</comments>
		<pubDate>Tue, 05 Jul 2011 14:04:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78262</guid>
		<description><![CDATA[Endo Pharmaceuticals (ENDP) recently suffered a pipeline setback with its candidate axomadol performing disappointingly in a mid-stage trial (n=236). Top line results from the study revealed that Endo Pharma’s candidate failed to meet the predetermined end points. The randomized, double blind, two-arm, placebo-controlled study evaluated the candidate in patients suffering from moderate-to-severe chronic low back pain. Endo Pharma in-licensed the US and Canadian development and marketing rights of axomadol from Grunenthal in 2009. The 4-week study evaluated the candidate at doses ranging from 100 mg/day to 300 mg/day. The maintenance phase of the study was 12 weeks. The main goal was a change in the average intensity of pain measured by a numerical rating scale from baseline to the final week of treatment for all patients who were treated with ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/05/endp-endo-pharmaceuticals-back-pain-drug-disappoints/78262/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENDP) Endo Pharmaceuticals Announces FDA Action Date</title>
		<link>http://www.stockbloghub.com/2011/06/27/endp-endo-pharmaceuticals-announces-fda-action-date/77598</link>
		<comments>http://www.stockbloghub.com/2011/06/27/endp-endo-pharmaceuticals-announces-fda-action-date/77598#comments</comments>
		<pubDate>Mon, 27 Jun 2011 18:46:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77598</guid>
		<description><![CDATA[Endo Pharmaceuticals (ENDP) recently announced that the US Food and Drug Administration (FDA) has issued a new action date for the new formulation of painkiller Opana ER. The FDA stated that it will review Endo Pharma’s response to the agency’s complete response letter (CRL) by December 13, 2011. The new formulation of Opana ER is designed to resist attempts of crushing, breaking, pulverizing or making a powder of the product. The candidate aims to bring relief to patients suffering from moderate-to-severe pain and in need of continuous opioid treatment for an extended period of time. CRL Issued in January 2011 On January 7, 2011, Endo Pharma announced that the FDA had issued a CRL for the painkiller. Even though the US regulatory body declined to approve the new formulation of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/27/endp-endo-pharmaceuticals-announces-fda-action-date/77598/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Analyst Mintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/24/ctic-cell-therapeutics-analyst-mintains-neutral-on-shares/77315</link>
		<comments>http://www.stockbloghub.com/2011/06/24/ctic-cell-therapeutics-analyst-mintains-neutral-on-shares/77315#comments</comments>
		<pubDate>Fri, 24 Jun 2011 16:03:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[MDS]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Midas Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77315</guid>
		<description><![CDATA[We are maintaining a Neutral recommendation on Cell Therapeutics Inc. (CTIC) with a target price of $2.25. Cell Therapeutics Inc. based in Seattle, Washington, is focused on developing drugs for cancer. The company’s lead pipeline candidate, pixantrone, is being developed for the treatment of hematologic malignancies and solid tumors. In December 2010, Cell Therapeutics filed an appeal against the decision of the FDA in April 2010 to deny approval to pixantrone for the treatment of relapsed, aggressive non-Hodgkin&#8217;s lymphoma, or NHL, in patients who have not responded to other treatment options. The approval was denied due to concerns that the late stage trial PIX301 (which formed the basis of the NDA filing) had not sufficiently proved the effectiveness of the drug. The FDA asked Cell Therapeutics to conduct an additional ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/ctic-cell-therapeutics-analyst-mintains-neutral-on-shares/77315/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENDP) Endo Pharmaceuticals Holdings Buys American Medical</title>
		<link>http://www.stockbloghub.com/2011/06/22/endp-endo-pharmaceuticals-holdings-buys-american-medical/77023</link>
		<comments>http://www.stockbloghub.com/2011/06/22/endp-endo-pharmaceuticals-holdings-buys-american-medical/77023#comments</comments>
		<pubDate>Wed, 22 Jun 2011 14:55:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77023</guid>
		<description><![CDATA[Recently, Endo Pharmaceuticals Holdings Inc. (ENDP) completed the purchase of American Medical Systems, a leading pelvic-health device provider, in an all cash deal worth approximately $2.9 billion. By acquiring American Medical, Endo Pharma, a US-based specialty healthcare solutions company that develops branded products and specialty generics, diversified its business and bolstered its urology portfolio. Endo Pharma, while announcing the deal in April 2011, stated that it expected the deal to be accretive to its adjusted earnings with immediate effect following the closure. Endo Pharma had also announced that it expected its 2012 and 2013 adjusted earnings to be boosted by $0.60 and $0.80 per share respectively, as a result of the merger. We note that the purchase of American Medical is the fourth major acquisition for Endo Pharma over the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/endp-endo-pharmaceuticals-holdings-buys-american-medical/77023/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Set to Resubmit Pixantrone NDA</title>
		<link>http://www.stockbloghub.com/2011/06/17/ctic-cell-therapeutics-set-to-resubmit-pixantrone-nda/76603</link>
		<comments>http://www.stockbloghub.com/2011/06/17/ctic-cell-therapeutics-set-to-resubmit-pixantrone-nda/76603#comments</comments>
		<pubDate>Fri, 17 Jun 2011 14:50:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76603</guid>
		<description><![CDATA[Cell Therapeutics (CTIC) recently met with the Division of Oncology Drug Products (the DODP) of the US Food and Drug Administration (FDA) and received guidance for resubmission of the new drug application (NDA) for its lead pipeline candidate pixantrone. Pixantrone has been developed for the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma (NHL) in patients who have not responded to other treatment options. The company is also looking for accelerated approval of the NDA based on data from the PIX301 study. The meeting follows the early May decision of the Office of New Drugs (OND) of the FDA allowing the company to re-submit the NDA for pixantrone for review without the need for an additional trial. The OND recommended Cell Therapeutics to conduct an additional independent radiologic review utilizing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/17/ctic-cell-therapeutics-set-to-resubmit-pixantrone-nda/76603/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Seeks Generic Viagra Approval</title>
		<link>http://www.stockbloghub.com/2011/06/16/wpi-watson-pharmaceuticals-seeks-generic-viagra-approval/75582</link>
		<comments>http://www.stockbloghub.com/2011/06/16/wpi-watson-pharmaceuticals-seeks-generic-viagra-approval/75582#comments</comments>
		<pubDate>Thu, 16 Jun 2011 15:09:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Consolidated Edison Inc.]]></category>
		<category><![CDATA[ED]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75582</guid>
		<description><![CDATA[Watson Pharmaceuticals Inc. (WPI) recently announced that it has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) to market its generic version of Pfizer Inc.’s (PFE) erectile dysfunction (ED) drug, Viagra sildenafil citrate tablets. In response, Pfizer has filed a lawsuit against Watson Pharma in the United States District Court for the Southern District of New York. Since Pfizer filed a suit within 30 days of the ANDA filing, the FDA cannot approve Watson Pharma’s generic Viagra until November 6, 2013 or until the court ruling, whichever is earlier. Watson Pharma is seeking approval for the 25 mg, 50 mg and 100 mg dosage formulations of sildenafil citrate tablets. Viagra sales amounted to $1.9 billion in 2010. Last month, Watson Pharma launched the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/16/wpi-watson-pharmaceuticals-seeks-generic-viagra-approval/75582/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Outlook &#8211; June 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371</link>
		<comments>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371#comments</comments>
		<pubDate>Wed, 15 Jun 2011 03:24:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76371</guid>
		<description><![CDATA[Challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts continue to impact the pharmaceutical industry. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Products like Lipitor, Plavix, Lexapro and Zyprexa are expected to face generic competition over the next five years. In fact, 2011 itself will see drugs worth more than $30 billion losing patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the same time, new products are ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Launches Generic Drugs</title>
		<link>http://www.stockbloghub.com/2011/05/21/myl-mylan-launches-generic-drugs/74321</link>
		<comments>http://www.stockbloghub.com/2011/05/21/myl-mylan-launches-generic-drugs/74321#comments</comments>
		<pubDate>Sat, 21 May 2011 13:54:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[ISTA]]></category>
		<category><![CDATA[ISTA Pharmaceuticals Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74321</guid>
		<description><![CDATA[MylanInc. (MYL) recently launched its generic version of Ista Pharmaceuticals Inc’s (ISTA) Xibrom ophthalmic solution, used for the treatment of inflammation in patients who have undergone a cataract extraction operation. The generic has been launched under a development and supply agreement with Coastal Pharmaceuticals. The branded product recorded sales of $116 million in US for the twelve months ending on March 31, 2011. Mylan also recently announced launches of generic versions of Cephalon’s (CEPH) Amrix which is a muscle relaxant and Johnson &#38; Johnson’s (JNJ) Risperdal which is used for the treatment of schizophrenia. As of May 16, 2011, the company had 169 abbreviated new drug applications (ANDAs) pending US Food and Drug Administration (FDA) approval targeting $100.7 billion in branded sales. Mylan believes that about 45 of the pending ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/21/myl-mylan-launches-generic-drugs/74321/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRX) Valeant Pharmaceuticals Beats Earnings Estimates on Revenues</title>
		<link>http://www.stockbloghub.com/2011/05/18/vrx-valeant-pharmaceuticals-beats-earnings-estimates-on-revenues/73944</link>
		<comments>http://www.stockbloghub.com/2011/05/18/vrx-valeant-pharmaceuticals-beats-earnings-estimates-on-revenues/73944#comments</comments>
		<pubDate>Wed, 18 May 2011 15:22:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73944</guid>
		<description><![CDATA[Valeant Pharmaceuticals International‘s (VRX) first quarter 2011 earnings of 49 cents per share (excluding special items but including stock-based compensation expense) missed the Zacks Consensus Estimate by 2 cents and the year-ago earnings by 10 cents per share. Revenues for the quarter increased to $565 million, well above the Zacks Consensus Estimate of $517 million and the prior-year quarter’s revenue of $219.6 million. However, revenue included a one-time alliance and royalty revenue of $36 million related to the March 2011 out-licensing of product rights to Cloderm cream, a mid-potency steroid to Dr. Reddy&#8217;s Laboratories (RDY). Excluding the one-time payment, revenue was $529 million, which was still above both the Zacks Consensus Estimate and the prior-year revenue. Organically (excluding the impact of one-time revenues, acquisitions and foreign exchange), revenues grew 7% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/18/vrx-valeant-pharmaceuticals-beats-earnings-estimates-on-revenues/73944/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BOBE) Company News for May 11, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/05/11/bobe-company-news-for-may-11-2011-corporate-summary/73828</link>
		<comments>http://www.stockbloghub.com/2011/05/11/bobe-company-news-for-may-11-2011-corporate-summary/73828#comments</comments>
		<pubDate>Wed, 11 May 2011 16:16:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Restaurants]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Bob Evans Farms Inc.]]></category>
		<category><![CDATA[BOBE]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Chesapeake Utilities Corporation]]></category>
		<category><![CDATA[Cisco Systems]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[Cosan Limited]]></category>
		<category><![CDATA[CPK]]></category>
		<category><![CDATA[Credit Suisse Group]]></category>
		<category><![CDATA[CS]]></category>
		<category><![CDATA[CSCO]]></category>
		<category><![CDATA[CZZ]]></category>
		<category><![CDATA[Dean Foods Company]]></category>
		<category><![CDATA[DF]]></category>
		<category><![CDATA[DHX]]></category>
		<category><![CDATA[Dice Holdings Inc]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GPK]]></category>
		<category><![CDATA[Graphic Packaging Holding Company]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[NGLS]]></category>
		<category><![CDATA[PANL]]></category>
		<category><![CDATA[Targa Resources Partners LP]]></category>
		<category><![CDATA[Universal Display Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73828</guid>
		<description><![CDATA[•    Microsoft Corp. (NASDAQ:MSFT) will purchase internet communications leader Skype from the investor consortium led by Silver Lake. The deal which is worth $8.5 billion in cash has been approved by the boards of directors of both companies •    Dean Foods (NYSE:DF) reported Q1 EPS of $0.14, surpassing the Zacks Consensus Estimate of $0.06 per share •    Medical-device maker Boston Scientific Corporation (NYSE:BSX) announced that Ray Elliott would retire as president and CEO at the end of the year •    Shares of online technology-jobs sites operator DICE HOLDINGS, INC. (NYSE:DHX) dropped 5.5% a day after the company revealed that “certain stockholders” would sell 8 million shares. •    Share prices of MannKind Corp.(NASDAQ:MNKD) plunged 12.3% a day after the biotechnology firm  reported a first-quarter loss exceeding expectations •    Late on Monday, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/11/bobe-company-news-for-may-11-2011-corporate-summary/73828/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon First Quarter 2011 Earnings Miss Expectations</title>
		<link>http://www.stockbloghub.com/2011/05/05/ceph-cephalon-first-quarter-2011-earnings-miss-expectations/73295</link>
		<comments>http://www.stockbloghub.com/2011/05/05/ceph-cephalon-first-quarter-2011-earnings-miss-expectations/73295#comments</comments>
		<pubDate>Thu, 05 May 2011 15:46:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73295</guid>
		<description><![CDATA[Cephalon Inc. (CEPH) delivered first quarter earnings of $1.98 per share, several cents below the Zacks Consensus Estimate of $2.04 but 12.5% above the year-ago earnings of $1.76. First quarter revenues, which increased 24.9% to $745.1 million, missed the Zacks Consensus Estimate of $752 million by a wide margin. First quarter results were within the guidance range provided by the company. Cephalon had guided towards adjusted net income of $144 &#8211; $159 million on sales of $725 &#8211; $755 million. The Quarter in Detail First quarter revenues consisted of $736 million in product sales (up 27.6%) and $9.1 million in other revenues. All segments performed well during the quarter. The central nervous system (CNS) and oncology franchises posted sales of $334.7 million (up 7%) and $149.1 million (up 35%), respectively. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/05/ceph-cephalon-first-quarter-2011-earnings-miss-expectations/73295/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Announces Aquisition of Cephalon</title>
		<link>http://www.stockbloghub.com/2011/05/03/teva-teva-pharmaceutical-industries-announces-aquisition-of-cephalon/73024</link>
		<comments>http://www.stockbloghub.com/2011/05/03/teva-teva-pharmaceutical-industries-announces-aquisition-of-cephalon/73024#comments</comments>
		<pubDate>Tue, 03 May 2011 18:10:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73024</guid>
		<description><![CDATA[Yet another acquisition deal was announced in the pharma sector with generic player, Teva Pharmaceutical Industries Ltd. (TEVA) entering into a definitive agreement with Cephalon, Inc. (CEPH). Teva intends to acquire Cephalon for $81.50 per share in cash or $6.8 billion. Teva Tops Valeant Bid Cephalon has been in the news over the past few weeks with Valeant Pharmaceuticals (VRX) expressing an interest in acquiring the company. Valeant had initially approached Cephalon in late March with a $73 bid. However, Cephalon rejected the offer. Teva’s offer price tops Valeant’s offer and represents a 39% premium to Cephalon’s stock price before Valeant’s unsolicited proposal was announced. Deal in line with Long-Term Strategy The Cephalon deal is in line with Teva’s long-term strategy of expanding and strengthening its branded and specialty pharma ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/03/teva-teva-pharmaceutical-industries-announces-aquisition-of-cephalon/73024/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AA) Company News for May 03, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/05/03/aa-company-news-for-may-03-2011-corporate-summary/73019</link>
		<comments>http://www.stockbloghub.com/2011/05/03/aa-company-news-for-may-03-2011-corporate-summary/73019#comments</comments>
		<pubDate>Tue, 03 May 2011 17:53:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Aluminum]]></category>
		<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[AA]]></category>
		<category><![CDATA[ACI]]></category>
		<category><![CDATA[Alcoa Inc.]]></category>
		<category><![CDATA[Arch Coal Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Community Health Systems Inc.]]></category>
		<category><![CDATA[CYH]]></category>
		<category><![CDATA[DISH]]></category>
		<category><![CDATA[Dish Network Corporation]]></category>
		<category><![CDATA[EchoStar Corporation]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Hologic Inc]]></category>
		<category><![CDATA[HOLX]]></category>
		<category><![CDATA[ICO]]></category>
		<category><![CDATA[International Coal Group Inc]]></category>
		<category><![CDATA[PFG]]></category>
		<category><![CDATA[Principal Financial Group Inc]]></category>
		<category><![CDATA[SATS]]></category>
		<category><![CDATA[SNE]]></category>
		<category><![CDATA[Sony Corporation]]></category>
		<category><![CDATA[Tenet Healthcare Corporation]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[THC]]></category>
		<category><![CDATA[TIVO]]></category>
		<category><![CDATA[TiVo Inc.]]></category>
		<category><![CDATA[VLCM]]></category>
		<category><![CDATA[Volcom Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73019</guid>
		<description><![CDATA[•    Arch Coal, Inc. (NYSE:ACI) and International Coal Group, Inc. (NYSE:ICO) announced that they have signed a definitive agreement under which Arch will acquire all of the outstanding shares of ICG for $14.60 per share in an all-cash transaction valued at $3.4 billion •    Teva Pharmaceutical (NASDAQ:TEVA) and Cephalon (NASDAQ:CEPH) said that their respective boards of directors unanimously approved a definitive agreement under which Teva will acquire Cephalon and all of its outstanding shares for $81.50 per share in cash, with a total enterprise value of about $6.8 billion •    Principal Financial Group (NYSE:PFG) reported Q1 EPS of $0.71, marginally higher than the Zacks Consensus Estimate of $0.70 per share. Revenues for the quarter rose 4% year-over-year to $2.05 billion, just short of the Zacks Consensus Estimate of $2.055 billion ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/03/aa-company-news-for-may-03-2011-corporate-summary/73019/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Stock Market News for May 3, 2011 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2011/05/03/ceph-stock-market-news-for-may-3-2011-market-news/73016</link>
		<comments>http://www.stockbloghub.com/2011/05/03/ceph-stock-market-news-for-may-3-2011-market-news/73016#comments</comments>
		<pubDate>Tue, 03 May 2011 17:53:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Chesapeake Energy Corporation]]></category>
		<category><![CDATA[CHK]]></category>
		<category><![CDATA[Community Health Systems Inc.]]></category>
		<category><![CDATA[CYH]]></category>
		<category><![CDATA[DISH]]></category>
		<category><![CDATA[Dish Network Corporation]]></category>
		<category><![CDATA[HUM]]></category>
		<category><![CDATA[Humana Inc.]]></category>
		<category><![CDATA[ICE]]></category>
		<category><![CDATA[Intercontinental Exchange]]></category>
		<category><![CDATA[Nasdaq OMX Group Inc]]></category>
		<category><![CDATA[NDAQ]]></category>
		<category><![CDATA[Nyse Euronext Inc]]></category>
		<category><![CDATA[NYX]]></category>
		<category><![CDATA[Tenet Healthcare Corporation]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[THC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73016</guid>
		<description><![CDATA[Late on Sunday, US President Barack Obama declared: “I determined that we had enough intelligence to take action and authorized an operation to get Osama bin Laden and bring him to justice….After a firefight, they killed Osama bin Laden and took custody of his body.” The press briefing instantly led to celebrations among citizens and the cheer was expected to be carried into the markets. However, the news of the death of the al-Qaida chief failed to sustain the gains for long. Combined with economic data and merger and acquisition news, markets rallied in the morning session, but thereafter declined modestly to end in the red. The Dow Jones Industrial Average (DJIA) dropped less than 0.1% to settle at 12,807.36. The Standard &#38; Poor 500 shed 0.2% to close at ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/03/ceph-stock-market-news-for-may-3-2011-market-news/73016/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BRCM) Company News for April 07, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/04/07/brcm-company-news-for-april-07-2011-corporate-summary/70919</link>
		<comments>http://www.stockbloghub.com/2011/04/07/brcm-company-news-for-april-07-2011-corporate-summary/70919#comments</comments>
		<pubDate>Thu, 07 Apr 2011 17:22:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Semiconductor - Integrated Circuits]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[BRCM]]></category>
		<category><![CDATA[Broadcom Corporation]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Cisco Systems]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[CSCO]]></category>
		<category><![CDATA[G]]></category>
		<category><![CDATA[Genpact Limited]]></category>
		<category><![CDATA[LGF]]></category>
		<category><![CDATA[Lions Gate Entertainment Corporation]]></category>
		<category><![CDATA[MON]]></category>
		<category><![CDATA[Monsanto Company]]></category>
		<category><![CDATA[Netflix Inc.]]></category>
		<category><![CDATA[NFLX]]></category>
		<category><![CDATA[Skyworks Solutions Inc.]]></category>
		<category><![CDATA[SWKS]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>
		<category><![CDATA[WD-40 Company]]></category>
		<category><![CDATA[WDFC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70919</guid>
		<description><![CDATA[• New York Times reported that Cephalon, Inc. (NASDAQ:CEPH) rejected Valeant Pharmaceuticals&#8217; (NYSE:VRX) unsolicited $5.7 billion takeover bid, citing the offer was too low and opportunistic • Monsanto Company (NYSE:MON) reported a Q2 EPS of $1.88 beating the Zacks Consensus Estimate of $1.08 per share • WD-40 Company (NASDAQ:WDFC) reported Q2 EPS of $0.53, lower than the Zacks Consensus Estimate of $0.60 per share. Revenues for the quarter fell 2% year-over-year to $79.2 million, missing the Zacks Consensus Estimate of $90.0 million • Genpact Ltd (NYSE:G) has agreed to acquire global IT consulting firm Headstrong Corp for $550 million. The deal is expected to close in May, and Genpact expects the company to add to its earnings for the year • According to reports, Citigroup (NYSE:C) is looking to expand its commodity investment-product team over ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/07/brcm-company-news-for-april-07-2011-corporate-summary/70919/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EIA) Stock Market News for March 31, 2011 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2011/03/31/eia-stock-market-news-for-march-31-2011-market-news/70353</link>
		<comments>http://www.stockbloghub.com/2011/03/31/eia-stock-market-news-for-march-31-2011-market-news/70353#comments</comments>
		<pubDate>Thu, 31 Mar 2011 19:14:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Closed-End Fund - Debt]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[American Express Company]]></category>
		<category><![CDATA[AT&T Inc.]]></category>
		<category><![CDATA[AXP]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Chesapeake Energy Corporation]]></category>
		<category><![CDATA[Chevron Corporation]]></category>
		<category><![CDATA[CHK]]></category>
		<category><![CDATA[ConocoPhillips]]></category>
		<category><![CDATA[COP]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[DFS]]></category>
		<category><![CDATA[Discover Financial Services]]></category>
		<category><![CDATA[Eaton Vance Insured California Municipal Bond Fund]]></category>
		<category><![CDATA[EIA]]></category>
		<category><![CDATA[Exxon Mobil Corporation]]></category>
		<category><![CDATA[MA]]></category>
		<category><![CDATA[Marathon Oil Corporation]]></category>
		<category><![CDATA[Mastercard Incorporated]]></category>
		<category><![CDATA[MRO]]></category>
		<category><![CDATA[T]]></category>
		<category><![CDATA[Tesoro Corporation]]></category>
		<category><![CDATA[TSO]]></category>
		<category><![CDATA[V]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[Valero Energy Corporation]]></category>
		<category><![CDATA[Visa Inc]]></category>
		<category><![CDATA[VLO]]></category>
		<category><![CDATA[VRX]]></category>
		<category><![CDATA[XOM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70353</guid>
		<description><![CDATA[Markets enjoyed an extended stay in the green following reports of new jobs being created in the private-sector. Domestic data was strong enough to counter any concerns arising from the euro-zone debt woes, Libyan unrest and the Japan nuclear crisis. The Dow inched closer to the levels of February 18, which was the highest close since June 5, 2008. The Dow Jones Industrial Average (DJIA) is en route to its best quarter performance and is within striking distance of reaching its highest levels for 2011. The gains come amidst a host of global tensions and it likely reflects the strength of the domestic economy, which has helped the indices recover from the damages it suffered. The Dow gained 0.6% to close at 12,350.61. The Standard &#38; Poor 500 (S&#38;P 500) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/31/eia-stock-market-news-for-march-31-2011-market-news/70353/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACXM) Company News for March 31, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/03/31/acxm-company-news-for-march-31-2011-corporate-summary/70355</link>
		<comments>http://www.stockbloghub.com/2011/03/31/acxm-company-news-for-march-31-2011-corporate-summary/70355#comments</comments>
		<pubDate>Thu, 31 Mar 2011 19:12:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Information Technology Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Acxiom Corporation]]></category>
		<category><![CDATA[ACXM]]></category>
		<category><![CDATA[ALGN]]></category>
		<category><![CDATA[Align Technology Inc]]></category>
		<category><![CDATA[BBY]]></category>
		<category><![CDATA[Best Buy Company Inc]]></category>
		<category><![CDATA[BlackRock Inc.]]></category>
		<category><![CDATA[BLK]]></category>
		<category><![CDATA[BRKR]]></category>
		<category><![CDATA[Bruker Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CONN]]></category>
		<category><![CDATA[Conns Inc.]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GEOI]]></category>
		<category><![CDATA[GeoResources Inc]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WFC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70355</guid>
		<description><![CDATA[• According to a report from Bloomberg, Valeant Pharmaceuticals (NYSE:VRX) made a hostile bid to acquire Cephalon (NASDAQ:CEPH) for about $73 a share in cash or about $5.7 billion, after earlier bids were rejected • Standard &#38; Poor’s said the world’s biggest asset manager BlackRock Inc (NYSE:BLK) would replace Genzyme Corp. (NASDAQ:GENZ)  in the S&#38;P 500 index  after Friday’s close • Wells Fargo Securities initiated coverage on exploration company GeoResources Inc. (NASDAQ:GEOI)  with an “Outperform” rating • Chinese internet company Qihoo 360 Technology Company (NYSE:QIHU) made its debut on the New York Stock Exchange with a bang with share prices rising 134.48% to close at $34.00 • Data-services provider Acxiom Corp (NASDAQ:ACXM) announced that its CEO had resigned, effective two days ago, and that its CFO plans to step down • Align Technologies (NASDAQ:ALGN) said it ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/31/acxm-company-news-for-march-31-2011-corporate-summary/70355/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Reports Very Strong Quarterly Earnings</title>
		<link>http://www.stockbloghub.com/2010/11/01/ceph-cephalon-reports-very-strong-quarterly-earnings/57105</link>
		<comments>http://www.stockbloghub.com/2010/11/01/ceph-cephalon-reports-very-strong-quarterly-earnings/57105#comments</comments>
		<pubDate>Mon, 01 Nov 2010 14:16:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=57105</guid>
		<description><![CDATA[Cephalon, Inc. (CEPH) delivered another strong quarter with earnings coming at $2.14 per share, easily beating the Zacks Consensus Estimate of $1.79 and well above the year-ago earnings of $1.62. Strong revenues, a favorable product mix and the company’s continuing efforts to improve operating leverage helped Cephalon post impressive results. Revenues increased 30.5% to $716.9 million. However, revenues fell short of the Zacks Consensus Estimate of $719 million. The Quarter in Detail Third quarter revenues consisted of $707.1 million in product sales (up 32%) and $9.9 million in other revenues. Revenues were driven by contributions from the central nervous system (CNS) and oncology franchises, which posted sales of $354.3 million (up 19%) and $132.9 million (up 60%), respectively. Revenues were also boosted by other product sales of $88.8 million, which ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/01/ceph-cephalon-reports-very-strong-quarterly-earnings/57105/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Analyst Cuts Shares to Underperform</title>
		<link>http://www.stockbloghub.com/2010/10/07/ctic-cell-therapeutics-analyst-cuts-shares-to-underperform/54305</link>
		<comments>http://www.stockbloghub.com/2010/10/07/ctic-cell-therapeutics-analyst-cuts-shares-to-underperform/54305#comments</comments>
		<pubDate>Thu, 07 Oct 2010 23:28:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=54305</guid>
		<description><![CDATA[We are downgrading Cell Therapeutics, Inc. (CTIC) to Underperform from Neutral with a price target of $0.25 primarily due to the uncertainty surrounding the US approval of its lead candidate, pixantrone. Pixantrone (proposed trade name: Pixuvri), is currently under development for the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma (NHL) in patients who have not responded to other treatment options. Cell Therapeutics Inc., based in Seattle, Washington, is focused on developing drugs for cancer. The company received a setback in April 2010, when the US Food and Drug Administration (FDA) denied approval to pixantrone and issued a complete response letter (CRL) based on issues related to the study design. The FDA asked Cell Therapeutics to conduct an additional trial to determine the safety and efficacy of pixantrone. In August ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/07/ctic-cell-therapeutics-analyst-cuts-shares-to-underperform/54305/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Files Lawsuit Against Apotex &#8211; Several Companies Challenging Nuvigil Patent</title>
		<link>http://www.stockbloghub.com/2010/08/21/ceph-cephalon-files-lawsuit-against-apotex-several-companies-challenging-nuvigil-patent/48718</link>
		<comments>http://www.stockbloghub.com/2010/08/21/ceph-cephalon-files-lawsuit-against-apotex-several-companies-challenging-nuvigil-patent/48718#comments</comments>
		<pubDate>Sat, 21 Aug 2010 18:28:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[EnergySolutions Inc]]></category>
		<category><![CDATA[ES]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48718</guid>
		<description><![CDATA[In a recent filing with the US Securities and Exchange Commission (SEC), Cephalon Inc. (CEPH) announced that it has filed a lawsuit in the US District Court in Delaware against Apotex Corp. and Apotex Inc. Apotex is seeking to launch a generic version of Cephalon’s sleep franchise product, Nuvigil. The lawsuit was filed in response to a Paragraph IV Certification Notice Letter received by Cephalon in July regarding an Abbreviated New Drug Application (ANDA) filed with the US Food and Drug Administration (FDA) by Apotex. The lawsuit has been filed under the provisions of the Hatch-Waxman Act, which means that the FDA cannot grant final approval for up to 30 months or until final resolution of the matter before the court, whichever occurs earlier. Several Companies Challenging Nuvigil Patent We ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/21/ceph-cephalon-files-lawsuit-against-apotex-several-companies-challenging-nuvigil-patent/48718/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Second Quarter 2010 Earnings Report Beats The Street</title>
		<link>http://www.stockbloghub.com/2010/07/28/ceph-cephalon-second-quarter-2010-earnings-report-beats-the-street/45093</link>
		<comments>http://www.stockbloghub.com/2010/07/28/ceph-cephalon-second-quarter-2010-earnings-report-beats-the-street/45093#comments</comments>
		<pubDate>Wed, 28 Jul 2010 18:55:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BDSI]]></category>
		<category><![CDATA[BioDelivery Sciences International Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=45093</guid>
		<description><![CDATA[Cephalon Inc. (CEPH) delivered another strong quarter with second quarter earnings coming in at $2.05 per share, six cents above the Zacks Consensus Estimate and well above the year-ago earnings of $1.44 per share. We note that the Zacks Consensus Estimate had been revised recently following Cephalon’s announcement that it expects to deliver second quarter earnings above its previously issued guidance. Strong revenues helped the company post impressive results. Revenue increased 32.7% to $726.9 million, exceeding the Zacks Consensus Estimate by almost $19 million. The Mepha acquisition contributed $90 million to second-quarter revenue. The Quarter in Detail Second-quarter revenue consisted of $712.4 million in product sales (up 32.2%) and $14.5 million in other revenue. Revenue was driven by contributions from the central nervous system (CNS) and oncology franchises, which posted ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/28/ceph-cephalon-second-quarter-2010-earnings-report-beats-the-street/45093/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Second Quarter 2010 Earnings Preview</title>
		<link>http://www.stockbloghub.com/2010/07/27/ceph-cephalon-second-quarter-2010-earnings-preview/44914</link>
		<comments>http://www.stockbloghub.com/2010/07/27/ceph-cephalon-second-quarter-2010-earnings-preview/44914#comments</comments>
		<pubDate>Tue, 27 Jul 2010 13:28:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44914</guid>
		<description><![CDATA[Cephalon Inc. (CEPH) is scheduled to report second quarter results on July 27, 2010 after the market closes. The current Zacks Consensus Estimate for the second quarter is $1.99 per diluted share, representing year-over-year growth of 38%. Cephalon has consistently surpassed earnings estimates with a four-quarter average of 10.1%, and second quarter earnings are also expected to top expectations by 4.5%. Last week, Cephalon revised its guidance for the quarter saying that it now expects basic adjusted income per common share in the range of $2.17-$2.22 on sales of $705million-$715 million. Earlier, Cephalon was expecting basic adjusted income of $1.65-$1.75 per share on net sales of $645 &#8211; $670 million. The Zacks Consensus Revenue Estimate is $708 million. Based on the revised expectations for the second quarter, Cephalon will also ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/27/ceph-cephalon-second-quarter-2010-earnings-preview/44914/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes&#8217; Quarterly Earnings Report Shows Revenue Dip</title>
		<link>http://www.stockbloghub.com/2010/05/17/alks-alkermes-quarterly-earnings-report-shows-revenue-dip/37429</link>
		<comments>http://www.stockbloghub.com/2010/05/17/alks-alkermes-quarterly-earnings-report-shows-revenue-dip/37429#comments</comments>
		<pubDate>Mon, 17 May 2010 22:27:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37429</guid>
		<description><![CDATA[Alkermes Inc. (ALKS) reported a fourth quarter fiscal 2010 net loss of 12 cents per share (excluding special items but including stock-based compensation) compared with a loss of 13 cents per share in the year-ago period; excluding the impact of the termination of  collaboration agreements with Cephalon Inc. (CEPH) and Eli Lilly &#38; Co. (LLY) but including stock-based compensation. The Zacks Consensus Estimate was a loss of 15 cents per share. Quarterly Results Total revenues for the reported quarter declined 12.3% year-over-year to $38.5 million. Manufacturing revenues for the fourth quarter of fiscal 2010 declined 8% year-over-year to $22.6 million. Royalty revenues for the quarter came in at $9.5 million. Research and development revenue under collaborative arrangements dropped to $0.4 million from $1.7 million in the year-ago quarter. The company also ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/17/alks-alkermes-quarterly-earnings-report-shows-revenue-dip/37429/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KG) King Pharmaceuticals&#8217; Quarterly Report Disappoints &#8211; Revenues Slide</title>
		<link>http://www.stockbloghub.com/2010/05/05/kg-king-pharmaceuticals-quarterly-report-disappoints-revenues-slide/36255</link>
		<comments>http://www.stockbloghub.com/2010/05/05/kg-king-pharmaceuticals-quarterly-report-disappoints-revenues-slide/36255#comments</comments>
		<pubDate>Wed, 05 May 2010 21:06:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[ZGEN]]></category>
		<category><![CDATA[ZymoGenetics Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=36255</guid>
		<description><![CDATA[King Pharmaceuticals Inc (KG) reported first-quarter earnings of 14 cents per share, well below the Zacks Consensus Estimate of 24 cents and the year-ago earnings of 26 cents. Revenues fell 11.2% from the year-ago quarter to $380.9 million. The Quarter in Detail King&#8217;s branded Pharmaceuticals segment declined 12.9% with revenues coming in at $242 million. Revenues of all key products excluding Flector Patch declined from the year-ago period. Thrombin-JMI sales declined to $37 million, down 21.3%. We expect Thrombin-JMI sales to continue declining due to the tough competition in the form of ZymoGenetics&#8216; (ZGEN) Recothrom and Omrix Biopharmaceuticals&#8216; (OMRI) Evithrom. Meanwhile, Skelaxin, which posted sales of $91 million (down 9.9%), is facing stiff competition from Cephalon&#8216;s (CEPH) Amrix. Amrix&#8217;s once-daily dosing regime and low rate of somnolence should provide it ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/05/kg-king-pharmaceuticals-quarterly-report-disappoints-revenues-slide/36255/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon&#8217;s Quarterly Earnings Report Beats &#8211; Updates Guidance</title>
		<link>http://www.stockbloghub.com/2010/05/05/ceph-cephalons-quarterly-earnings-report-beats-updates-guidance/36254</link>
		<comments>http://www.stockbloghub.com/2010/05/05/ceph-cephalons-quarterly-earnings-report-beats-updates-guidance/36254#comments</comments>
		<pubDate>Wed, 05 May 2010 20:57:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BDSI]]></category>
		<category><![CDATA[BioDelivery Sciences International Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=36254</guid>
		<description><![CDATA[Cephalon, Inc. (CEPH) started 2010 on a strong note with first quarter earnings beating expectations by a wide margin. The company reported first quarter earnings of $1.76 per share, 20 cents above the Zacks Consensus Estimate, and well above the year-ago earnings of $1.30. Top-line performance also remained strong with revenues increasing 14.7% to $596.6 million. The Quarter in Detail First quarter revenues consisted of $576.7 million in product sales (up 12%) and $19.9 million in other revenues. Revenues were driven by contributions from the central nervous system (CNS) and oncology franchises, which posted sales of $307.1 million (up 14%) and $110 million (up 44%), respectively. Oncology drug Treanda continued to perform well, with sales coming in at $81.3 million, up 62%. Growing acceptance among hematologists should boost sales further ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/05/ceph-cephalons-quarterly-earnings-report-beats-updates-guidance/36254/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Files New Drug Application For Vivitrol Expansion</title>
		<link>http://www.stockbloghub.com/2010/04/14/alks-alkermes-files-new-drug-application-for-vivitrol-expansion/33706</link>
		<comments>http://www.stockbloghub.com/2010/04/14/alks-alkermes-files-new-drug-application-for-vivitrol-expansion/33706#comments</comments>
		<pubDate>Wed, 14 Apr 2010 21:16:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33706</guid>
		<description><![CDATA[Recently Alkermes, Inc. (ALKS) submitted a supplemental New Drug Application (sNDA) for Vivitrol (naltrexone for extended-release injectable suspension) to the US Food and Drug Administration (FDA) for treating opioid dependence. Opioid dependence refers to a chronic ailment of the brain. The affected individual continues to use opioids despite the damage caused by it. Vivitrol, an injectable opioid antagonist administered once-monthly, is already available as an injectable medication for alcohol dependence. The drug received FDA approval in 2006. Vivitrol was initially marketed by Cephalon (CEPH) in the US. However, Cephalon terminated its collaboration with Alkermes ever since December 1, 2008. Alkermes entered into an exclusive agreement with Cilag GmbH International, a subsidiary of Johnson &#38; Johnson (JNJ), to commercialize Vivitrol in Russia and other countries in the Commonwealth Independent States (CIS) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/14/alks-alkermes-files-new-drug-application-for-vivitrol-expansion/33706/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Completes Aquisition of Generic Drug Company Mepha AG</title>
		<link>http://www.stockbloghub.com/2010/04/12/ceph-cephalon-completes-aquisition-of-generic-drug-company-mepha-ag/33501</link>
		<comments>http://www.stockbloghub.com/2010/04/12/ceph-cephalon-completes-aquisition-of-generic-drug-company-mepha-ag/33501#comments</comments>
		<pubDate>Tue, 13 Apr 2010 03:39:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33501</guid>
		<description><![CDATA[Cephalon, Inc. (CEPH) recently announced the completion of its acquisition of Mepha AG, a privately-held Swiss generic drug company, for CHF 662.4 million (approximately $615.4 million). This acquisition marks Cephalon’s entry in the generics market. This deal is in-line with Cephalon’s goal to reduce its dependence on its central nervous system (CNS) franchise for long-term growth. The company’s CNS franchise, which consists of Nuvigil, Provigil and Gabitril, is its primary growth driver. However, Provigil is slated to face generic competition from 2012 and Nuvigil is facing patent challenges from generic players like Teva (TEVA) and Mylan (MYL). As such, Cephalon is looking to supplement long-term growth by acquiring/in-licensing products. The Mepha acquisition will not only allow Cephalon to enter the generic drug market, it will also allow the company to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/12/ceph-cephalon-completes-aquisition-of-generic-drug-company-mepha-ag/33501/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Completes Acquisition of Ception Therapeutics</title>
		<link>http://www.stockbloghub.com/2010/04/06/ceph-cephalon-completes-acquisition-of-ception-therapeutics/32938</link>
		<comments>http://www.stockbloghub.com/2010/04/06/ceph-cephalon-completes-acquisition-of-ception-therapeutics/32938#comments</comments>
		<pubDate>Tue, 06 Apr 2010 21:04:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32938</guid>
		<description><![CDATA[Cephalon, Inc. (CEPH) recently announced the completion of its acquisition of biotechnology company Ception Therapeutics, Inc. With this acquisition, Cephalon will gain access to Ception&#8217;s lead product, Cinquil (reslizumab), an investigational humanized monoclonal antibody (mAb) against interleukin-5 (IL-5). Earlier this year, Ception reported positive results on Cinquil from a phase II study that was conducted in adults with eosinophilic asthma. Results showed that Cinquil improved asthma control in adult patients with moderate to severe asthma and eosinophilic airway inflammation. Moreover, Cinquil also achieved statistical significance compared to placebo in an analysis of FEV1, which is a measure of lung function. Based on these results, Cephalon decided to exercise its option to acquire Ception. The company intends to move the candidate into phase III studies for the treatment of eosinophilic asthma. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/06/ceph-cephalon-completes-acquisition-of-ception-therapeutics/32938/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Experiences Regulatory Setback</title>
		<link>http://www.stockbloghub.com/2010/03/31/ceph-cephalon-experiences-regulatory-setback/32392</link>
		<comments>http://www.stockbloghub.com/2010/03/31/ceph-cephalon-experiences-regulatory-setback/32392#comments</comments>
		<pubDate>Wed, 31 Mar 2010 20:13:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32392</guid>
		<description><![CDATA[Cephalon, Inc. (CEPH) suffered a regulatory setback recently with its failure to receive outright approval from the US Food and Drug Administration (FDA) for its supplemental new drug application (sNDA) for Nuvigil. Cephalon was seeking to get Nuvigil approved for the treatment of patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel. Cephalon had submitted data from a study that was conducted under the FDA’s special protocol assessment process. The company had evaluated the efficacy of the drug based on two primary endpoints: an objective assessment (the Multiple Sleep Latency Test), and a subjective assessment (the Patient Global Impression of Severity). Even though Nuvigil achieved statistical significance in both endpoints, the FDA has raised questions in its complete response letter regarding the strength of the subjective ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/31/ceph-cephalon-experiences-regulatory-setback/32392/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Earnings Estimates Up on Company Guidance</title>
		<link>http://www.stockbloghub.com/2010/03/16/ceph-cephalon-earnings-estimates-up-on-company-guidance/30685</link>
		<comments>http://www.stockbloghub.com/2010/03/16/ceph-cephalon-earnings-estimates-up-on-company-guidance/30685#comments</comments>
		<pubDate>Tue, 16 Mar 2010 22:00:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BDSI]]></category>
		<category><![CDATA[BioDelivery Sciences International Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30685</guid>
		<description><![CDATA[Earnings estimates for Cephalon, Inc. (CEPH) have gone up significantly following the issuance of a better-than-expected guidance by the company. Cephalon exited 2009 on a strong note with both fourth-quarter and full-year earnings exceeding expectations. Cephalon reported fourth-quarter earnings of $1.66 per share, up 13.7%, and full-year earnings of $6.03, up 25%. Top-line performance also remained strong with fourth quarter revenues increasing 6.5% to $575.1 million, and full year revenues increasing 11% to $2.2 billion. Revenues were primarily driven by contributions from the central nervous system (CNS) and oncology franchises. Guidance and Earnings Estimate Revisions Cephalon’s guidance for 2010, which was re-issued following the company’s decision to acquire generic company Mepha, was well above expectations and resulted in several analysts raising their earnings estimates for the stock. Earnings estimates for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/16/ceph-cephalon-earnings-estimates-up-on-company-guidance/30685/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KG) King Pharmaceuticals Misses Earnings Expectations by a Penny</title>
		<link>http://www.stockbloghub.com/2010/02/28/kg-king-pharmaceuticals-misses-earnings-expectations-by-a-penny/29115</link>
		<comments>http://www.stockbloghub.com/2010/02/28/kg-king-pharmaceuticals-misses-earnings-expectations-by-a-penny/29115#comments</comments>
		<pubDate>Mon, 01 Mar 2010 04:15:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Pain Therapeutics Inc.]]></category>
		<category><![CDATA[PTIE]]></category>
		<category><![CDATA[ZGEN]]></category>
		<category><![CDATA[ZymoGenetics Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29115</guid>
		<description><![CDATA[King Pharmaceuticals, Inc. (KG) reported fourth-quarter earnings of 23 cents per share, a penny below the Zacks Consensus Estimate. Despite fourth quarter revenues increasing 26.1% from the year-ago period, earnings declined 20.6% from the year-ago quarter, mainly due to higher operating expenses. Full-year earnings, which came in a couple of cents above the Zacks Consensus Estimate at $1.10, declined 28.6% from the year-ago period. Meanwhile, full-year revenues increased 14% to $1.78 billion. Fourth-Quarter Performance Fourth-quarter revenues came in at $439.1 million. King&#8217;s branded pharmaceuticals segment remained flat with revenues coming in at $277 million. While Avinza revenues remained flat, both Skelaxin and Thrombin-JMI sales continued to decline on a year-over-year basis. Thrombin-JMI sales came in at $44 million, down 22.8%. We expect Thrombin-JMI sales to continue declining due to the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/28/kg-king-pharmaceuticals-misses-earnings-expectations-by-a-penny/29115/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Beats Earnings Expectations and Guides Higher</title>
		<link>http://www.stockbloghub.com/2010/02/12/ceph-cephalon-beats-earnings-expectations-and-guides-higher/27882</link>
		<comments>http://www.stockbloghub.com/2010/02/12/ceph-cephalon-beats-earnings-expectations-and-guides-higher/27882#comments</comments>
		<pubDate>Fri, 12 Feb 2010 17:20:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BDSI]]></category>
		<category><![CDATA[BioDelivery Sciences International Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27882</guid>
		<description><![CDATA[Cephalon, Inc. (CEPH) exited 2009 on a strong note with both fourth quarter and full year earnings exceeding expectations. The company reported fourth quarter earnings of $1.66 per share, 6 cents above the Zacks Consensus Estimate, and 13.7% above the year-ago earnings. Full year earnings came in at $6.03, easily surpassing the Zacks Consensus Estimate of $5.96 and the year-ago earnings of $4.82. Top-line performance also remained strong with fourth quarter revenues increasing 6.5% to $575.1 million, and full year revenues increasing 11% to $2.2 billion. Fourth Quarter Performance Fourth quarter revenues consisted of $562.9 million in product sales (up 5.2%) and $12.2 million in other revenues. Revenues were driven by contributions from the central nervous system (CNS) and oncology franchises, which posted sales of $302.4 million (up 1.6%) and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/12/ceph-cephalon-beats-earnings-expectations-and-guides-higher/27882/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Reports Lower Third Quarter Loss</title>
		<link>http://www.stockbloghub.com/2010/02/05/alks-alkermes-reports-lower-third-quarter-loss/27199</link>
		<comments>http://www.stockbloghub.com/2010/02/05/alks-alkermes-reports-lower-third-quarter-loss/27199#comments</comments>
		<pubDate>Sat, 06 Feb 2010 01:24:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27199</guid>
		<description><![CDATA[Alkermes Inc. (ALKS) reported a third quarter fiscal 2010 net loss of 3 cents per share (excluding items but including stock based compensation) compared with a loss of 9 cents in the year-ago period (excluding the impact of the termination of the collaboration agreements with Cephalon Inc. (CEPH) for Vivitrol but including stock based compensation). Estimate Revisions Trend Two of the 10 analysts covering the stock for the next quarter raised their earnings estimates over the last 30 days while none moved in the opposite direction. This means that majority of them have not revised their estimates for the next quarter, additionally the revision is marginal. Furthermore, two of the 9 analysts covering the stock for the next fiscal year raised their earnings estimates over the last 30 days while ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/05/alks-alkermes-reports-lower-third-quarter-loss/27199/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Enters Generics Market</title>
		<link>http://www.stockbloghub.com/2010/02/02/ceph-cephalon-enters-generics-market/26804</link>
		<comments>http://www.stockbloghub.com/2010/02/02/ceph-cephalon-enters-generics-market/26804#comments</comments>
		<pubDate>Wed, 03 Feb 2010 01:07:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26804</guid>
		<description><![CDATA[Cephalon Inc. (CEPH) has recently signed a deal which should mark the company’s entry into the generics business. The company announced that it intends to acquire Mepha AG, a privately held Swiss generic drug company for approximately $590 million (CHF 622.5 million). This deal is in-line with Cephalon’s goal to reduce its dependence on its central nervous system (CNS) franchise for long-term growth. The company’s CNS franchise, which consists of Nuvigil, Provigil and Gabitril, is its primary growth driver. However, Provigil is slated to face generic competition from 2012 and Nuvigil is facing patent challenges from generic players such as Teva (TEVA), Watson Pharmaceuticals (WPI) and Mylan (MYL). Given this scenario, Cephalon is looking to supplement long-term growth by acquiring/in-licensing products. The Mepha acquisition will not only allow Cephalon to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/02/ceph-cephalon-enters-generics-market/26804/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon&#8217;s Nuvigil Under Pressure From Another Potential Generic Version</title>
		<link>http://www.stockbloghub.com/2010/01/07/ceph-cephalons-nuvigil-under-pressure-from-another-potential-generic-version/24415</link>
		<comments>http://www.stockbloghub.com/2010/01/07/ceph-cephalons-nuvigil-under-pressure-from-another-potential-generic-version/24415#comments</comments>
		<pubDate>Thu, 07 Jan 2010 17:47:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24415</guid>
		<description><![CDATA[Cephalon Inc.’s (CEPH) Nuvigil remains under pressure as yet another generic company is seeking to market a generic version of the drug. Watson Pharmaceuticals, Inc. (WPI) recently confirmed that it has filed an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA) seeking approval to market its generic version of four dosage strengths (50 mg, 100 mg, 150mg, 200 mg, and 250mg) of Nuvigil. Watson believes it is first to file on the 100 and 200 mg dosage strengths, which means that it will enjoy 180 days of generic market exclusivity on the approval and launch of these dosage strengths. As expected, Cephalon has filed a lawsuit against Watson so as to prevent the latter from launching its product prior to the expiration of U.S. Patent ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/07/ceph-cephalons-nuvigil-under-pressure-from-another-potential-generic-version/24415/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRX) Valeant Pharmaceuticals International Drug Accepted by FDA</title>
		<link>http://www.stockbloghub.com/2010/01/04/vrx-valeant-pharmaceuticals-international-drug-accepted-by-fda/24088</link>
		<comments>http://www.stockbloghub.com/2010/01/04/vrx-valeant-pharmaceuticals-international-drug-accepted-by-fda/24088#comments</comments>
		<pubDate>Mon, 04 Jan 2010 17:54:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24088</guid>
		<description><![CDATA[Recently, Valeant Pharmaceuticals International (VRX) announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for marketing approval for its drug candidate retigabine. Retigabine is a neuronal potassium channel opener indicated for treating adult epilepsy patients with partial-onset seizures. Valeant has high hopes for its seizure drug, which is co-developed with GlaxoSmithKline PLC (GSK). The agreement pertains to the development and marketing of the drug in the U.S., Canada, Puerto Rico, Australia and New Zealand. Glaxo has exclusive rights pertaining to retigabine elsewhere. Retigabine displayed encouraging results in late-stage studies reducing seizure rates compared to a placebo. The most common adverse effects are dizziness, fatigue, vertigo, tremor, abnormal coordination, diplopia, disturbance in attention, asthenia and blurring of vision. The thrice-a-day pill could get the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/04/vrx-valeant-pharmaceuticals-international-drug-accepted-by-fda/24088/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Learns FDA Delays Nuvigil Decision</title>
		<link>http://www.stockbloghub.com/2009/12/28/ceph-cephalon-learns-fda-delays-nuvigil-decision/23738</link>
		<comments>http://www.stockbloghub.com/2009/12/28/ceph-cephalon-learns-fda-delays-nuvigil-decision/23738#comments</comments>
		<pubDate>Tue, 29 Dec 2009 01:25:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23738</guid>
		<description><![CDATA[The U.S. Food and Drug Administration (FDA) recently informed Cephalon, Inc. (CEPH) that it will require more time to review the supplemental new drug application (sNDA) submitted by the company for Nuvigil. Cephalon had filed the sNDA in June 2009, seeking to expand Nuvigil’s label as a treatment for improving wakefulness in patients with excessive sleepiness associated with jet lag disorder due to eastbound travel. The FDA had initially granted priority review status to the candidate which means a decision would have been out by Dec 29, 2009. However, with the agency asking for additional review time, a decision is now expected by March 29, 2010. Nuvigil (armodafinil) is a follow-on version of Provigil (modafinil) which contributed about 50% to revenues in 2008. Cephalon received FDA approval for Nuvigil in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/28/ceph-cephalon-learns-fda-delays-nuvigil-decision/23738/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon: After Hard Fall &#8211; This Stock Is Set for a Comeback</title>
		<link>http://www.stockbloghub.com/2009/12/16/ceph-cephalon-after-hard-fall-this-stock-is-set-for-a-comeback/23028</link>
		<comments>http://www.stockbloghub.com/2009/12/16/ceph-cephalon-after-hard-fall-this-stock-is-set-for-a-comeback/23028#comments</comments>
		<pubDate>Wed, 16 Dec 2009 22:57:07 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23028</guid>
		<description><![CDATA[by Sheena Martin, Contributing Editor Wednesday, December 16, 2009 One company looking forward to the end of 2009 is Cephalon (Nasdaq: CEPH). And that’s an understatement. The biopharmaceutical company’s share price has tumbled by 23% this year, following a slide in sales. On top of that, clinical results for a drug that treats inflation of the esophagus in children were disappointing. And generic drugs threaten its other flagship products. However, the growth potential is still significant, given promising trial results for its new cancer drug… Cephalon’s $1 Billion Drug Blockbuster In March 2008, Cephalon’s cancer treatment drug, Treanda, showed good results in patients with chronic lymphocytic leukemia – a cancer of the soft tissue inside bones where blood cells are made. Right now, it’s awaiting word from the Food and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/16/ceph-cephalon-after-hard-fall-this-stock-is-set-for-a-comeback/23028/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Drug Gains on Positive Data</title>
		<link>http://www.stockbloghub.com/2009/12/11/ceph-cephalon-drug-gains-on-positive-data/22630</link>
		<comments>http://www.stockbloghub.com/2009/12/11/ceph-cephalon-drug-gains-on-positive-data/22630#comments</comments>
		<pubDate>Fri, 11 Dec 2009 22:51:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22630</guid>
		<description><![CDATA[Cephalon, Inc. (CEPH) oncology product Treanda could see a significant rise in demand thanks to encouraging data presented at the recently conducted annual meeting of the American Society of Hematology (ASH). Clinical data supporting the use of Treanda as a new standard of care in the first-line treatment of non-Hodgkin&#8217;s lymphoma (NHL) was presented at ASH. Data from an investigator-led proof-of-concept study demonstrated that newly diagnosed NHL patients who were treated with a combination of Treanda and Roche/Genentech&#8216;s Rituxan experienced superior progression-free survival (55 months) compared to patients treated with the current standard of care, Rituxan plus a chemotherapy cocktail known as CHOP (35 months). The Rituxan-Treanda therapy was also found to be safer, less toxic and better tolerated. Treanda is currently approved for the treatment of patients suffering from ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/11/ceph-cephalon-drug-gains-on-positive-data/22630/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Sues Actavis Over Attempted Generic Launch</title>
		<link>http://www.stockbloghub.com/2009/12/11/ceph-cephalon-sues-actavis-over-attempted-generic-launch/22641</link>
		<comments>http://www.stockbloghub.com/2009/12/11/ceph-cephalon-sues-actavis-over-attempted-generic-launch/22641#comments</comments>
		<pubDate>Fri, 11 Dec 2009 22:47:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22641</guid>
		<description><![CDATA[In a filing with the U.S. Securities and Exchange Commission (SEC), Cephalon, Inc. (CEPH) announced that it has filed a lawsuit in the US District Court in Delaware against Actavis Group, Actavis Pharma Manufacturing Pvt. Ltd. and Actavis Inc. Actavis is seeking to launch a generic version of Cephalon’s sleep franchise product, Nuvigil. The lawsuit was filed in response to a Paragraph IV Certification Notice Letter received by Cephalon in November regarding an Abbreviated New Drug Application (ANDA) filed with the US Food and Drug Administration (FDA) by Actavis. Nuvigil (armodafinil) is the follow-on version of Provigil (modafinil), which contributed about 50% to revenues in 2008. With Provigil slated to face generics from 2012, Cephalon is looking to protect its sleep franchise sales by switching patients to Nuvigil. Cephalon is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/11/ceph-cephalon-sues-actavis-over-attempted-generic-launch/22641/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme&#8217;s Announces Positive Campath Oncology Results</title>
		<link>http://www.stockbloghub.com/2009/12/10/genz-genzymes-campath-announces-positive-oncology-results/22495</link>
		<comments>http://www.stockbloghub.com/2009/12/10/genz-genzymes-campath-announces-positive-oncology-results/22495#comments</comments>
		<pubDate>Thu, 10 Dec 2009 21:27:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22495</guid>
		<description><![CDATA[Genzyme Corp. (GENZ) recently presented encouraging interim results on its oncology product, Campath, at the annual meeting of the American Society of Hematology (ASH). Results from the randomized phase III study (CAM314) showed that Campath, when used in combination with Fludara (FluCAM), significantly reduced the risk of disease progression or death compared to single-agent Fludara in patients with relapsed and refractory chronic lymphocytic leukemia (CLL). Interim results showed that the FluCAM arm demonstrated superior progression free survival (PFS) compared to Fludara alone (29.6 months versus 20.7 months), reducing the risk of disease progression or death by 39%. Importantly, in a pre-specified subgroup of patients with advanced CLL, the median PFS was more than doubled with FluCAM compared to Fludara alone (26.1 months versus 12.1 months). The FluCAM regimen provided significantly ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/10/genz-genzymes-campath-announces-positive-oncology-results/22495/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon&#8217;s Pipeline Candidate Cinquil Disappoints</title>
		<link>http://www.stockbloghub.com/2009/12/07/ceph-cephalons-pipeline-candidate-cinquil-disappoints/22134</link>
		<comments>http://www.stockbloghub.com/2009/12/07/ceph-cephalons-pipeline-candidate-cinquil-disappoints/22134#comments</comments>
		<pubDate>Mon, 07 Dec 2009 19:21:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22134</guid>
		<description><![CDATA[Cephalon, Inc. (CEPH) recently reported disappointing results on a pipeline candidate, Cinquil that was being developed for the treatment of pediatric eosinophilic esophagitis (EoE). Results from the phase IIb/III study showed that Cinquil achieved a statistically significant reduction in esophageal eosinophil levels versus placebo, which was one of the co-primary endpoints. However, although patients on Cinquil showed an improvement in clinical symptoms, which was the second co-primary endpoint, the candidate failed to show a statistically significant improvement for this endpoint. Eosinophilic esophagitis is a rare disease that is more frequently diagnosed in children. The Journal of Clinical Investigation estimates that approximately 80,000 children in the United States have EoE. Cinquil is being developed by Ception Therapeutics, Inc., a privately held biopharmaceutical company and Cephalon holds an option to acquire Ception. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/07/ceph-cephalons-pipeline-candidate-cinquil-disappoints/22134/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Inc Sues Teva Pharmaceuticals</title>
		<link>http://www.stockbloghub.com/2009/12/04/ceph-cephalon-inc-sues-teva-pharmaceuticals/22030</link>
		<comments>http://www.stockbloghub.com/2009/12/04/ceph-cephalon-inc-sues-teva-pharmaceuticals/22030#comments</comments>
		<pubDate>Sat, 05 Dec 2009 01:53:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22030</guid>
		<description><![CDATA[Recently, Cephalon, Inc. (CEPH) filed a patent infringement lawsuit against generic player Teva Pharmaceuticals (TEVA), which is seeking to market a generic version of Cephalon’s sleep franchise product, Nuvigil. The lawsuit was filed in response to a Paragraph IV Certification Notice Letter received by Cephalon in October regarding an Abbreviated New Drug Application (ANDA) filed with the U.S. Food and Drug Administration (FDA) by Teva. Teva is seeking approval for its generic version of the 50 mg, 100 mg, 150 mg, 200 mg and 250 mg dosage strengths of Nuvigil. Nuvigil (armodafinil) is the follow-on version of Provigil (modafinil), which contributed about 50% to revenues in 2008. With Provigil slated to face generics from 2012, Cephalon is looking to protect its sleep franchise sales by switching patients to Nuvigil. Cephalon ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/04/ceph-cephalon-inc-sues-teva-pharmaceuticals/22030/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Settles Barr Pharmaceuticals Challenge</title>
		<link>http://www.stockbloghub.com/2009/11/25/ceph-cephalon-settles-barr-pharmaceuticals-challenge/21374</link>
		<comments>http://www.stockbloghub.com/2009/11/25/ceph-cephalon-settles-barr-pharmaceuticals-challenge/21374#comments</comments>
		<pubDate>Thu, 26 Nov 2009 05:51:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BDSI]]></category>
		<category><![CDATA[BioDelivery Sciences International Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21374</guid>
		<description><![CDATA[Earlier this month, Cephalon Inc. (CEPH) announced that it has settled its patent infringement case with Barr Pharmaceuticals, which is now owned by Teva Pharmaceutical (TEVA). Barr was looking to market a generic version of Cephalon’s cancer pain management drug, Fentora. As per the terms of the agreement, Barr has been granted a non-exclusive, royalty-free right to sell a generic version of Fentora in October 2018. However, if a generic version of Fentora enters the market prior to that date, Barr will be allowed to launch its generic version provided the other generic company does not enjoy marketing exclusivity. According to Cephalon, Fentora’s patent is not set to expire before 2019. While we are pleased to hear about this settlement agreement with Barr, we note that another major generic player, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/25/ceph-cephalon-settles-barr-pharmaceuticals-challenge/21374/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen&#8217;s Rituxan Label Expansion Delayed</title>
		<link>http://www.stockbloghub.com/2009/11/20/biib-biogens-rituxan-label-expansion-delayed/21038</link>
		<comments>http://www.stockbloghub.com/2009/11/20/biib-biogens-rituxan-label-expansion-delayed/21038#comments</comments>
		<pubDate>Fri, 20 Nov 2009 23:28:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21038</guid>
		<description><![CDATA[Biogen Idec (BIIB) and Genentech, Inc., a wholly-owned member of the Roche Group (RHHBY.PK), announced that they have received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for Rituxan. The companies were seeking approval for the use of Rituxan (rituximab) plus fludarabine and cyclophosphamide (FC) in patients with previously untreated and treated chronic lymphocytic leukemia (CLL). Although the companies did not provide any details regarding the letter, they said that the agency has not asked them to submit any new data. Genentech and Biogen intend to work towards gaining final approval for the expanded indication and are planning to continue final label discussions with the FDA. Rituxan is currently approved for the treatment of rheumatoid arthritis and non-Hodgkin’s lymphoma (NHL), a type of cancer. It ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/20/biib-biogens-rituxan-label-expansion-delayed/21038/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

